Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

CV ansehen CV ausblenden

Aktuelle News & Insights

Life Sciences & Healthcare

Shield Therapeutics enters transformational collaboration agreement with Viatris and raises debt and equity finance

6. Januar 2023

von Andrew Edge

Klicken Sie hier für Details

Recognition for our expertise as Life Sciences Team of the Year

24. November 2022

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Aspen Healthcare sold to Canadian-based property trust

27. September 2021

von Andrew McLean und Andrew Edge

Klicken Sie hier für Details
Life Sciences & Healthcare

Advising Apollo Therapeutics on $145 million financing

21. Juni 2021

von Andrew Edge und Chris Cowley

Klicken Sie hier für Details

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.